Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR0.30), versus (EUR0.18) reported last year. Revenue for the quarter came in at EUR2.1 million, versus EUR3.3 million reported last year.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Tutor Perini launches $400M senior notes offering due 2033
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target